Welcome to the Novo Nordisk Inc. ISS Management system for
investigator-sponsored studies. This site allows you to submit
an application to Novo Nordisk for ISS support and is restricted
to the submission of ISS grant requests only. If you would like
to submit a grant request for an independent medical education
program, please visit
Please allow a minimum of 60 days for full review of an
application. Novo Nordisk cannot approve an ISS application for
a study that is already in progress.
Please note that submission of an application does not mean that
Novo Nordisk has agreed to provide support for your study.
Decisions are made only after Novo Nordisk has made a
comprehensive review of your complete application. All requests
are reviewed for scientific merit, compliance with legal,
ethical and professional obligation, as well as fiscal
Thank you for considering Novo Nordisk as a partner in
scientific research. We look forward to reviewing your
For additional information regarding the ISS submission process,
here for a
Quick Reference Guide.
For any clarifications on data required to complete the
application, please email
If you need assistance, please call + 1 718-576-1406 or click here to
contact your system administrator.
Please read these terms and conditions of use carefully before using
this Novo Nordisk Inc site. By using a Novo Nordisk Inc. site and
any third-party site that is linked to a Novo Nordisk Inc. site you
signify your agreement to these terms. Novo Nordisk Inc. reserves
the right to change, modify, add, or remove portions of these terms.
Please check these terms periodically for changes. Your continued
use of a Novo Nordisk Inc. site following the posting of changes to
these terms will mean that you accept those changes.
Novo Nordisk Inc. sites are produced, owned and operated by Novo
Nordisk Inc. and its parent company, Novo Nordisk A/S, and are
protected by copyright and trademark laws. All materials contained
in any Novo Nordisk Inc. site are the copyright property of Novo
Nordisk Inc. or its parent company, Novo Nordisk A/S, or its
subsidiaries or affiliate companies and/or third-party licensors.
Novo Nordisk Inc. is one subsidiary of Novo Nordisk A/S among other
companies in the Novo Nordisk group of companies. Neither these
affiliate companies nor the parent company can be held responsible,
either directly or indirectly, for any harm, damage or inconvenience
that might arise from the use of this site, or from your reliance on
any information or materials provided on this site, or any
third-party site linked to or from this site.
All trademarks, servicemarks and tradenames are proprietary to Novo
Nordisk Inc., its parent company or its affiliates. No material from
any Novo Nordisk Inc. site owned, operated, licensed, or controlled
by us or our affiliates or parent company may be copied reproduced,
republished, uploaded, posted, transmitted, or distributed, in any
way, except that you may download one copy of the materials or
forward pages from this site, you must (i) not alter any copyrights
or other proprietary notices, (ii) make no modifications to the
materials, (iii) you may not use the materials in a manner that
suggests an association with any of our products, services or
brands, and (iv) you may not download quantities of materials to a
database that can be used to avoid future downloads from any Novo
Nordisk Inc. site. For purposes of these terms, the use of any such
material on any other website or computer environment is prohibited.
Novo Nordisk Safety Reporting Requirements Policy
Obligations and responsibilities of the Sponsor-Investigator related to safety reporting
When reporting Adverse Events the following parameters must be recorded:
- Study name
- Patient identification (e.g. subject number, initials, sex, age)
- Event (preferably a diagnosis)
- Drug (e.g. Norditropin Simplex®)
- Reporter identification (e.g. name, or initials)
a) Reporting to Health Authorities
The Sponsor-Investigator shall be responsible for all required periodic updates to health authorities and expedited reporting of Adverse Events occurring during the performance of the study, in accordance with local regulations and the agreed protocol.
The approving Health Authority may:
- Have special requests beyond Serious Unexpected Suspected Adverse Reaction (SUSAR) reporting
- Allow not to unblind and expedite specific SUSARs
Sponsor-investigators have obligations for reporting of relevant serious adverse events (SAE) information to the Competent Authority and Independent Ethics Committee/ Institutional Review Boards based upon federal regulations and Local/IRB policies.
b) Reporting to Novo Nordisk
For all IIS studies, when the Principal Investigator is aware that the study subject has been exposed to a Novo Nordisk product (including placebo, if supplied by Novo Nordisk), the following information must be reported in English to Novo Nordisk:
All individual Serious Adverse Drug Reactions (SADRs) shall be sent to Novo Nordisk within the same timeline as if they were reportable to regulatory authorities.
- SADRs include all SAEs which are probably or possibly related to any Novo Nordisk product.
- Indicate on any SADR whether it has been submitted to local health authorities.
- In addition to SADRs, any other events that have been submitted to the health authorities according to local regulatory requirements in the participating country shall be sent to Novo Nordisk at the time of submission to health authorities.
Report any pregnancy in the study subject that occurs during the use of a Novo Nordisk product.
- Pregnancies include pregnancies that occur in patients receiving Novo Nordisk products or pregnancies that occur in trial subject's partners whose foetus or baby develops an adverse event considered to be related to the trial product.
- SADRs and pregnancy reports are to be reported to Novo Nordisk via the approved Local Regulatory form (i.e FDA Medwatch form, CIOMS, etc.) An Event Fax Cover sheet will be provided by Novo Nordisk.
- Reportable Events subject to this provision are those that occur from the first dose of Novo Nordisk product, through the specified time period described in the protocol.
- The Principal Investigator shall provide further information about safety related events to NN, if the Principal Investigator receives specific requests from Novo Nordisk.
- The Principal Investigator also agrees to assist Novo Nordisk with follow-up of only SAE Reports.
Reporting the SAE to Novo Nordisk does not relieve institution and/or Principal Investigator of the responsibility for reporting it to the FDA or Local Regulatory authority, as required.
- The Sponsor-Investigator agrees to the terms of Novo Nordisk safety reporting policy for IIS Studies.
- The Sponsor-Investigator agrees to comply with Adverse Event reporting required by federal regulations and Local/IRB policies.
- Should Novo Nordisk agree to providing funding and/or drug for my IIS, I agree to Register the Trial Information, Status and results under applicable rules on clinicaltrials.gov and other Relevant sites.
- The protocol describes the ethical principles under which the study will be conducted (e.g. ICH, GCP), the manner in which the study will be reviewed by IRB/IACUC, and the procedures for obtaining informed consent.
I certify that the statements made in this request application are true, complete and accurate to the best of my knowledge.
By clicking here, you have read, understand and agree to all of the
above terms and conditions.